BioWorld

Feb. 28, 2008

FDA Pledges Renewed Focus to Boost Post-Market Safety

More than 100 years after the creation of the FDA, the agency said it now will apply the same standards it uses in its premarket drug reviews to manage its post-marketing safety process. (BioWorld Today) Read More

Regeneron Gets FDA's OK for Arcalyst in CAPS

New Connections of Clotting to Inflammation in Sepsis, MS

NewCo News: Profectus Seeks a Bio Niche Hitting HIV from all Angles

Biogen, Elan Nicked on Reports of Tysabri-Linked Liver Injuries

RegeneRx Secures $5M for Wound Healing Trials

Receptor Logic Finds Partner to Develop T-Cell Mimics

Other News To Note

Earnings Roundup

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 4, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

EASL 2026: Emerging liver disease targets to watch

BioWorld

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...